Zurueck zur Suche

Reporte zur Charge 335N9

Verknuepft ueber VAERS_ID mit VAERSDATA, Vax und Symptoms

6Reporte angezeigt
0Todesfaelle
0Hospitalisiert
0Lebensbedrohlich
0Bleibende Schaeden
CA 3 TX 2 IL 1

VAERS 2622212

GLAXOSMITHKLINE BIOLOGICALS · HIB (HIBERIX) · Charge 335N9

gering
Staat
TX
Alter
1,0
Geschlecht
F
Eingang
27.04.2023
Impfdatum
26.04.2023
Beginn
26.04.2023
Tage bis Beginn
0,0
Dosis
4
Route/Site
IM / RL
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: unbekannt
Unevaluable event

Symptomtext

None reported

Weitere VAERSDATA-Felder
Praegender Schweregrund
Unevaluable event
Hospital-Tage
-
Labordaten
None needed
Aktuelle Erkrankungen
Upper Respiratory Disease
Vorgeschichte
-
Andere Medikamente
NA
Allergien
NA
Vorherige Impfungen
-

VAERS 2517555

GLAXOSMITHKLINE BIOLOGICALS · HIB (HIBERIX) · Charge 335N9

gering
Staat
IL
Alter
0,3
Geschlecht
U
Eingang
28.11.2022
Impfdatum
19.08.2022
Beginn
-
Tage bis Beginn
-
Dosis
2
Route/Site
- / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Skin discolouration

Symptomtext

Gray dot on thigh; This case was reported by a nurse and described the occurrence of skin discoloration in a infant patient who received DTPa-HBV-IPV (Pediarix) (batch number X9HS4, expiry date unknown) for prophylaxis. Co-suspect products included dtpa-hbv-ipv vaccine pre-filled syringe device (Pediarix Pre-Filled Syringe Device) injection syringe for prophylaxis and Hib (Hiberix) (batch number 335N9, expiry date unknown) for prophylaxis. Previously administered products included pediarix with an associated reaction of skin discolouration (received 1st dose on 20th June 2022, refer link case US2022AMR171169) and hiberix with an associated reaction of skin discolouration (received 1st dose on 20th June 2022, refer link case US2022AMR171169). On 19th August 2022, the patient received the 2nd dose of Pediarix, Pediarix Pre-Filled Syringe Device and the 2nd dose of Hiberix. On an unknown date, less than 3 months after receiving Pediarix, Pediarix Pre-Filled Syringe Device and Hiberix, the patient experienced skin discoloration. On an unknown date, the outcome of the skin discoloration was unknown. It was unknown if the reporter considered the skin discoloration to be related to Pediarix, Pediarix Pre-Filled Syringe Device and Hiberix. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Linked case(s) involving the same patient: US2022AMR171169 Additional Information: GSK Receipt Date: 16-NOV-2022 Reporter's Comments: The patient experienced gray dots noted on legs (right thigh) after receiving Pediarix, Hiberix The reporter was consented to follow up. Additional supportive information: This was 1 of several linked cases, reported by same reporter.; Sender's Comments: US-GSK-US2022AMR171025:Same reporter US-GSK-US2022AMR171007:Same reporter US-GSK-US2022AMR171034:Same reporter US-GSK-US2022AMR171044:Same reporter US-GSK-US2022AMR171042:Same reporter US-GSK-US2022AMR171039:Same reporter US-GSK-US2022AMR171028:Same reporter US-GSK-US2022AMR149561:Same reporter US-GSK-US2022AMR149560:Same reporter US-GSK-US2022AMR149551:Same reporter US-GSK-US2022AMR148962:Same reporter US-GSK-US2022AMR148961:Same reporter US-GSK-US2022AMR148919:Same reporter US-GSK-US2022AMR171056:Same reporter US-GSK-US2022AMR171052:Same reporter US-GSK-US2022AMR171062:Same reporter US-GSK-US2022AMR171050:Same reporter US-GSK-US2022AMR171048:Same reporter US-GSK-US2022AMR171083:Same reporter US-GSK-US2022AMR171088:Same reporter US-GSK-US2022AMR171095:Same reporter US-GSK-US2022AMR171047:Same reporter US-GSK-US2022AMR171154:Same reporter US-GSK-US2022AMR171088:Same reporter US-GSK-US2022AMR171095:Same reporter US-GSK-US2022AMR171083:Same reporter US-GSK-US2022AMR171154:Same reporter US-GSK-US2022AMR171169:Same reporter US-GSK-US2022AMR171047:Same reporter US-GSK-US2022AMR171095:Same reporter US-GSK-US2022AMR171083:Same reporter US-GSK-US2022AMR171088:Same reporter US-GSK-US2022AMR171154:Same reporter US-GSK-US2022AMR171197:Same reporter US-GSK-US2022AMR171230:Same reporter US-GSK-US2022AMR171264:Same reporter US-GSK-US2022AMR148961: US-GSK-US2022AMR149560: US-GSK-US2022AMR149561:

Weitere VAERSDATA-Felder
Praegender Schweregrund
Skin discolouration
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 2463948

GLAXOSMITHKLINE BIOLOGICALS · HIB (HIBERIX) · Charge 335N9

gering
Staat
TX
Alter
0,3
Geschlecht
M
Eingang
29.09.2022
Impfdatum
19.09.2022
Beginn
29.08.2022
Tage bis Beginn
-
Dosis
2
Route/Site
- / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Inappropriate schedule of product administration Product administered to patient of inappropriate age

Symptomtext

1st dose on 29/08/2022, 2nd dose on 19/09/2022 (Rotarix/ Hiberix/ Pediarix); Hiberix and Pediarix 1st dose given at 3.6 months age; This case was reported by a other health professional via call center representative and described the occurrence of inappropriate age at vaccine administration in a 3-month-old male patient who received DTPa-HBV-IPV (Pediarix) (batch number X9HF4, expiry date 25th March 2024) for prophylaxis. Co-suspect products included dtpa-hbv-ipv vaccine pre-filled syringe device (Pediarix Pre-Filled Syringe Device) injection syringe for prophylaxis, Hib (Hiberix) (batch number 335N9, expiry date 25th May 2023) for prophylaxis, Rota (Rotarix lyophilized formulation) (batch number 2339G, expiry date 16th February 2024) for prophylaxis, rotavirus vaccine oral applicator device (Rotarix Oral Applicator Device) oral applicator for prophylaxis, DTPa-HBV-IPV (Pediarix) for prophylaxis, dtpa-hbv-ipv vaccine pre-filled syringe device (Pediarix Pre-Filled Syringe Device) injection syringe for prophylaxis and Hib (Hiberix) for prophylaxis. Concomitant products included LIVE ATTENUATED HUMAN ROTAVIRUS G1 STRAIN (ROTARIX LYOPHILIZED FORMULATION). On 19th September 2022, the patient received the 2nd dose of Pediarix, Pediarix Pre-Filled Syringe Device, the 2nd dose of Hiberix, the 2nd dose of Rotarix lyophilized formulation and Rotarix Oral Applicator Device. On 29th August 2022, the patient received the 1st dose of Pediarix, Pediarix Pre-Filled Syringe Device and the 1st dose of Hiberix. On 29th August 2022, not applicable after receiving Pediarix, Pediarix Pre-Filled Syringe Device, Hiberix, Rotarix lyophilized formulation and Rotarix Oral Applicator Device and unknown after receiving Pediarix, Pediarix Pre-Filled Syringe Device, Hiberix and ROTARIX LYOPHILIZED FORMULATION, the patient experienced inappropriate age at vaccine administration. On 19th September 2022, the patient experienced drug dose administration interval too short. On an unknown date, the outcome of the inappropriate age at vaccine administration and drug dose administration interval too short were unknown. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK receipt date: 20-SEP-2022 Reporters comment: The medical assistant reported the patient received Pediarix, Hiberix, Rotarix on 29th Aug 2022 then received the same vaccines early on 19th Sep 2022 at patient's 4-month checkup. The medical assistant stated the patient was behind on vaccines and came in 29th Aug 2022 to catch up. The reporter did not consent to follow-up. Additional Supportive information: The patient received 1st dose of Hiberix and Pediarix at 3.6 months age, which led to inappropriate age at vaccine administration and received 2nd dose of Rotarix, Hiberix and Pediarix earlier than recommended time interval which led to shortening of vaccination schedule.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Inappropriate schedule of product administration
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 2273048

GLAXOSMITHKLINE BIOLOGICALS · HIB (HIBERIX) · Charge 335N9

gering
Staat
CA
Alter
-
Geschlecht
U
Eingang
12.05.2022
Impfdatum
26.04.2022
Beginn
26.04.2022
Tage bis Beginn
0,0
Dosis
UNK
Route/Site
- / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Incorrect dose administered Product preparation issue

Symptomtext

Administered hiberix without the diluent; Administered hiberix without the diluent; This case was reported by a nurse via call center representative and described the occurrence of inappropriate preparation of medication in a patient who received Hib (Hiberix) (batch number 335N9, expiry date unknown) for prophylaxis. On 26th April 2022, the patient received Hiberix. On 26th April 2022, unknown after receiving Hiberix, the patient experienced inappropriate preparation of medication and inappropriate dose of vaccine administered. On an unknown date, the outcome of the inappropriate preparation of medication and inappropriate dose of vaccine administered were unknown. Additional Information: GSK Receipt Date: 09-May-2022 Reporter's Comments: Registered nurse reported that, there were 3 vaccines that were administered hiberix without the diluent. She was unaware of how these vaccines were reconstituted so were unable to give any information. The reporter consented to follow up. Additional Supportive Information: The patient received Hiberix without the diluent, which led to inappropriate preparation of medication and inappropriate dose of vaccine administered. This is 1 of the 3 linked cases, reported by the same reporter.; Sender's Comments: US-GLAXOSMITHKLINE-US2022AMR076035:Same reporter. US-GLAXOSMITHKLINE-US2022AMR076036:Same reporter.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Incorrect dose administered
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 2273012

GLAXOSMITHKLINE BIOLOGICALS · HIB (HIBERIX) · Charge 335N9

gering
Staat
CA
Alter
-
Geschlecht
U
Eingang
12.05.2022
Impfdatum
26.04.2022
Beginn
26.04.2022
Tage bis Beginn
0,0
Dosis
UNK
Route/Site
- / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Incorrect dose administered Product preparation issue

Symptomtext

Administered hiberix without the diluent; Administered hiberix without the diluent; This case was reported by a nurse via call center representative and described the occurrence of inappropriate preparation of medication in a patient who received Hib (Hiberix) (batch number 335N9, expiry date unknown) for prophylaxis. On 26th April 2022, the patient received Hiberix. On 26th April 2022, unknown after receiving Hiberix, the patient experienced inappropriate preparation of medication and inappropriate dose of vaccine administered. On an unknown date, the outcome of the inappropriate preparation of medication and inappropriate dose of vaccine administered were unknown. Additional Information: GSK Receipt Date: 09-May-2022 Reporter's Comments: Registered nurse reported that, there were 3 vaccines that were administered hiberix without the diluent. She was unaware of how these vaccines were reconstituted so were unable to give any information. The reporter consented to follow up. Additional Supportive Information: The patient received Hiberix without the diluent, which led to inappropriate preparation of medication and inappropriate dose of vaccine administered. This is 1 of the 3 linked cases, reported by the same reporter.; Sender's Comments: US-GLAXOSMITHKLINE-US2022AMR076035:Same reporter. US-GLAXOSMITHKLINE-US2022075751:Same reporter.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Incorrect dose administered
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 2273011

GLAXOSMITHKLINE BIOLOGICALS · HIB (HIBERIX) · Charge 335N9

gering
Staat
CA
Alter
-
Geschlecht
U
Eingang
12.05.2022
Impfdatum
26.04.2022
Beginn
26.04.2022
Tage bis Beginn
0,0
Dosis
UNK
Route/Site
- / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Incorrect dose administered Product preparation issue

Symptomtext

Administered hiberix without the diluent; Administered hiberix without the diluent; This case was reported by a nurse via call center representative and described the occurrence of inappropriate preparation of medication in a patient who received Hib (Hiberix) (batch number 335N9, expiry date unknown) for prophylaxis. On 26th April 2022, the patient received Hiberix. On 26th April 2022, unknown after receiving Hiberix, the patient experienced inappropriate preparation of medication and inappropriate dose of vaccine administered. On an unknown date, the outcome of the inappropriate preparation of medication and inappropriate dose of vaccine administered were unknown. Additional Information: GSK Receipt Date: 09-May-2022 Reporter's Comments: Registered nurse reported that, there were 3 vaccines that were administered hiberix without the diluent. She was unaware of how these vaccines were reconstituted so were unable to give any information. The reporter consented to follow up. Additional Supportive Information: The patient received Hiberix without the diluent, which led to inappropriate preparation of medication and inappropriate dose of vaccine administered. This is 1 of the 3 linked cases, reported by the same reporter.; Sender's Comments: US-GLAXOSMITHKLINE-US2022075751:Same reporter.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Incorrect dose administered
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-